Shares of Novavax fell 20% at close of trading on Friday after U.S. regulatory filings raised concerns about the drug company’s Corona vaccine.
Summary documents released by the U.S. Food and Drug Administration have shown that there are some potential heart risks posed by the Novavax vaccine, while the U.S. agency has expressed positive results related to the efficacy of the Omicron mutant vaccine. “.
Novavax said in a statement in response to US agency documents that there is no conclusive evidence of a link between Novavax’s Corona vaccine and any heart infections, stressing that it will continue to monitor developments. .
Novavax is still awaiting approval for the emergency use of a coronavirus vaccine as a meeting of experts and advisers from the US Food and Drug Administration is scheduled next Tuesday.
Shares of Novavax fell 20% to $44.76 late in trading on Friday before rising 0.6% in post-session trading.
Source: El Iktisad
